Pyxis Oncology vs Zentalis Pharmaceuticals
PYXS and ZNTL side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How PYXS and ZNTL compare
Pyxis Oncology and Zentalis Pharmaceuticals are about the same size, with market caps of $151M and $140M.
Zentalis Pharmaceuticals scores higher on the StockData Score (6 against 5 for Pyxis Oncology), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | PYXS | ZNTL |
|---|---|---|
| Size and price | ||
| Market cap | $151M | $140M |
| Share price | $1.81 | $1.96 |
| Change, 1 year | −45.3% | 28.1% |
| Change, 5 years | −85.0% | −97.6% |
| Beta (5Y) | 1.62 | 2.12 |
| Employees | 56 | 106 |
| StockData Score | ||
| Total score | 5 | 6 (better) |
| Valuation score | 0 | 1 (better) |
| Growth score | 0 | 0 |
| Performance score | 0 | 0 |
| Health score | 5 | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/B | 13.2× | 1.0× (better) |
| FCF yield | – | −91.2% |
| Profitability | ||
| Return on equity | −179% | −66.7% (better) |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 1.34 | 4.82 (better) |
| Altman Z-score | −15.78 | −8.63 (better) |
| Piotroski F-score | 1 | 1 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 40.9% | 66.1% |
| Held by insiders | 20.4% | 58.0% |
| Insider net buying, 12 months | −$107K | $12.8M (better) |
| Short interest, % of float | 7.4% | 19.8% |
Go deeper
- PYXS stock overview
- PYXS income statement
- PYXS valuation and score
- ZNTL stock overview
- ZNTL income statement
- ZNTL valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.